Mata: Key success factors for PM: starts at target selection; all projects in all Rx areas are in-scope for assessing;... #Tricon
6:36pm February 20th 2017 via Hootsuite
Mata: Shows slide of low- to med- to high-risk pts, from low likelihood of bacterial infection, to high, incr. sophistication PMDx #Tricon
6:33pm February 20th 2017 via Hootsuite
Mata: Current antibiotic Rx is 'educated guess'. Fig from '16 J Prec Med (PDF: https://t.co/8vLvfYNQ5b ) #Tricon
6:31pm February 20th 2017 via Hootsuite
Mata: Case study 3: Dx are 'crucial to solving the problem of antibacterial resistance'. Hazards: from concerning, serious, urgent #Tricon
6:29pm February 20th 2017 via Hootsuite
Mata: The first CDx for NGS: Oncology FoundationFOCUS CDx BRCA detects deleterious BRCA1/2, either germline or inh. (Myriad mention) #Tricon
6:28pm February 20th 2017 via Hootsuite
Mata: Combination for deltaF508 CF mutation. #Tricon The first NGS approval: came from CF in '12, MiSeqDx. 139-var assay.
6:26pm February 20th 2017 via Hootsuite
Mata: CF:the 'rare among the rare'. Kalydeco, '12 approved, 10 specific mutations (G551D, G1244E etc); also combination w/Orkambi #Tricon
6:25pm February 20th 2017 via Hootsuite
Mata: 2nd drug Maraviroc, '07 approved; '15 removed CDx PMA. Tropism assay 'required' = Companion Dx #Tricon
6:24pm February 20th 2017 via Hootsuite
Mata: One disease (HIV), two drugs, two Dx approaches: Abacavir ('98 approved), HLA*B5701, on-label rec'd screening for hypersens. #Tricon
6:23pm February 20th 2017 via Hootsuite
Mata: Obdivo compl. Dx; test is PMA approved, doesn't appear any of their labels. Keytruda comp. Dx; 1st line NSCLC PDL1+ #Tricon
6:22pm February 20th 2017 via Hootsuite
Mata: 3 drugs are 2 for chronic hep C by HCP genotype tests. And Exondys 51, anti-sense oligo for Duchenne's MD, a rare disease #Tricon
6:20pm February 20th 2017 via Hootsuite
Mata: And Rubraca (rucaparib) for ov ca based on BRCA1/2. First approval ofNGS as a CDx 'but not necessarily first approval for NGS' #Tricon
6:19pm February 20th 2017 via Hootsuite
Mata: '16 PMC report: 6 approved. 3 oncology; out of total 4 new oncology drugs for 2016. One PD-L1 CDx; CLL by 17p deletion; #Tricon
6:18pm February 20th 2017 via Hootsuite
Mata: Nucala for asthma based on eosinophil ct. Found population that responded. high-enough to respond, a regular Dx not CDx #Tricon
6:17pm February 20th 2017 via Hootsuite
Mata: Others - Daklinza for chronic hep C based on genotype 3 biomarker status; Orkambi for CF based on F508del/CFTR #Tricon
6:16pm February 20th 2017 via Hootsuite
Mata: '15 PMC annual report: 13 newly approved indications. 5 oncology, ALK, BRAF 'nothing novel!' Of the 8: schiz (2) on CYP2D6 #Tricon
6:15pm February 20th 2017 via Hootsuite
Mata: Complementary Dx - biomarker-defined set of pts, not on the label of the drug #Tricon
6:14pm February 20th 2017 via Hootsuite
Mata: Starts w/definitions: Dx, for disease, injury or medical condition. CDx: 'essential for safe and effective use for a drug' #Tricon
Marielena Mata (GlaxoSmithKline) Precision medicine beyond oncology #Tricon Starts w/ a cartoon
6:12pm February 20th 2017 via Hootsuite
Best: From 4 samples, showed good correlation between lancet blood drop and 6mL EDTA draws. #Tricon
6:04pm February 20th 2017 via Hootsuite
Best: Forr glioma: able to distinguish between lower and higher grades; showed heat-maps. Now trying method on blood drops (lancet) #Tricon
Best: Applying to early Br ca, Stg I-III pts, n=89. Able to get 70% spec at near 100% sensitivity (optimized for sens) #Tricon
6:02pm February 20th 2017 via Hootsuite
Best: Able to get 83% accuracy, with AUC 0.89 ROC. 1246-gene panel, can remove 40% non-responders for treatment. #Tricon
6:01pm February 20th 2017 via Hootsuite
Best: Applied SWARM-enhanced thromboseq method to Stg IV Nivolumab anti-PD1 response prediction. RECIST criteria. #Tricon
5:59pm February 20th 2017 via Hootsuite
Best: Showed data for ribosome binding site enrichment. SWARM-enhanced - for and optimum classifier (nice video of birds swarming) #Tricon
5:55pm February 20th 2017 via Hootsuite
Best: Number of spliced RNAs in platelets numbered above 4500. Determined sensitivity of 10-50M reads/sample sufficient #Tricon
5:51pm February 20th 2017 via Hootsuite
Best: Stg II-IV matching for age, smoking status, blood storage time for lung ca. 263 matched #Tricon
5:50pm February 20th 2017 via Hootsuite
Best: Low sample numbers; EDTA-storage time; non-age-matched cohorts; effect of inflammation. Thus 700 prospective smpls #Tricon
5:49pm February 20th 2017 via Hootsuite
Best: Showed algorithmic training, with training and test set. From their '15 ref https://t.co/iOgW2l1Mnm several comments #Tricon
5:48pm February 20th 2017 via Hootsuite
Best: Tumor-educated platelets (TEP) splice mRNAs. Able to show pan-cancer dx via TEP-derived spliced RNA gene panels #Tricon
5:47pm February 20th 2017 via Hootsuite
Best: #Tricon This first paper on platelet RNA https://t.co/mor4q62qSb led to this paper, a method thromboSeq https://t.co/U4jzzrlHtR
5:45pm February 20th 2017 via Hootsuite
Best: Points to this '14 ref and platelet's role in metastasis https://t.co/YBwanfKaoJ Platelets sequester RNA #Tricon
5:43pm February 20th 2017 via Hootsuite
Myron Best (VU Medical Center Amsterdam) Tumor-educated platelets as a blood-based liquid biopsy platform for cancer dx #Tricon
5:41pm February 20th 2017 via Hootsuite
Pantel: Shows great fig from '16 Clin Chem rev https://t.co/7W4FM22VLa about purposes and complementarity bet ctDNA and CTCs #Tricon
5:39pm February 20th 2017 via Hootsuite
Pantel: Also comparison of methodologies, dev of db's, dev of blood-based CDx and new drugs #Tricon
5:37pm February 20th 2017 via Hootsuite
Pantel: Has organized a consortium called CANCER-ID with dozens of organizations; https://t.co/rGIacrIpcs want SOPs for biobanking #Tricon
5:36pm February 20th 2017 via Hootsuite
Mouritzen: Exosomes are not only biomarker-containing, but also have biological function '15 Nature https://t.co/cUdEfiy7Ge #Tricon
5:34pm February 20th 2017 via Hootsuite
Pantel: Even platelets contain cancer-specific information '15 cancer cell https://t.co/idPCbqXStE #Tricon
5:33pm February 20th 2017 via Hootsuite
Klaus Pantel (Hamburg-Eppendorf Germany) New kits on the block for liquid biopsy #tricon
5:32pm February 20th 2017 via Hootsuite
Q: Any work on clin trial response monitoring? Mouritzen: No Q: Stat. treatment for signal? A: No normalization, paper in prep #Tricon
4:42pm February 20th 2017 via Hootsuite
Mouritzen: With and w/o exosome isolation, less powerful ROC, nonethless grey-zone group AUC 0.907, sens 88%, spec 95%. #Tricon
4:36pm February 20th 2017 via Hootsuite
Mouritzen: Then 227 individuals etc. currently in validation. Showed ROC curve of disocvery - Sens 88%, spec 95%. AUC 0.955 #Tricon
4:35pm February 20th 2017 via Hootsuite
Mouritzen: A full 'miR-ome': 752 miRNAs in 50 individuals; screen 259 w/188 subset; then 222 w/22 BPH, 200 PCa w/ 92 miR subset #Tricon
4:33pm February 20th 2017 via Hootsuite
Mouritzen: Their test - <2h from 3mL of urine, 20 min isolation; in discovery phase, have ID'd a 3-miRNA signature #Tricon
4:32pm February 20th 2017 via Hootsuite
Mouritzen: Thus Pr ca is overtreated; 2.3M biopsies; 1.5M could be avoided. #Tricon
4:31pm February 20th 2017 via Hootsuite
Mouritzen: And 7/10 are False Positives; 1/10 do have cancer; PSA grey-zone of 3-10ng/mL very low pred value (25%) 40% this zone #Tricon
Mouritzen: miRNA case study of pr ca in urine: reviews weakness of PSA test. 45M tests/yr, >1M new cases/yr (600K in EU and US) #Tricon
4:30pm February 20th 2017 via Hootsuite
Mouritzen: Shows nice concordance between their LNA qPCR system quant of fold-change to NGS data across >10 species of miRNAs. #Tricon
4:28pm February 20th 2017 via Hootsuite
Mouritzen: (Ratio of NGS:overlap:qPCR - NGS is isomiRs and not present on panels) #Tricon
4:27pm February 20th 2017 via Hootsuite
Mouritzen: When unbound by TPM (tags per million reads), about 900 spp of miRNAs detected. Shows Venn of NGS vs qPCR: 347:348:109 #Tricon
4:26pm February 20th 2017 via Hootsuite
